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ABSTRACT 
 
Background: Namibia is one of the Southern African countries hardest hit by the HIV 
epidemic, with an estimated one out of every five people infected (MoHSS, 2004). 
Approximately 80,000 of the infected population currently require antiretroviral treatment 
(ART). In order to prevent the progression of the HIV infection to AIDS, patients are 
required to take antiretroviral medicines lifelong. This lifelong use exposes patients to 
toxicities of these medicines and the only available options of managing the toxicities of 
ARVs are to treat the toxicity or substitute or switch the offending medicines.  
 
Aim: The current study aimed to describe the extent and reasons for substituting and 
switching HAART at the Katutura Intermediate Hospital in Windhoek, Namibia. 
 
Methodology: A descriptive retrospective case series study, in which medical records were 
reviewed to determine the extent and reasons for substituting and switching HAART was 
conducted. Random sampling was used to draw a sample of 500 from 3477 adult HAART 
patients who commenced treatment between 1 January 2002 and 31 December 2006. A pre-
piloted data collection tool was used to collect the data. The following information was 
collected: baseline CD4 count, weight, initial ARVs, first and second ARV substitutions, 
ART switch and the reasons for substituting ARVs or switching ART during the indicated 
period. Epi Info version 6 was used to analyse frequencies, means and medians of all 
important variables in the data set. 
 
Results: The sample was made up of 500 HAART patients; 60% were females. The median 
age of the sample was 34 years (Inter-quartile range (IQR) 30 – 40) and the median CD4 cell 
count was 153 cells/mm3 (IQR 96 – 212) at initiation of therapy. The median time on 
 
 
 
 
 vi
treatment before first substitution was 28 months (IQR 24 – 34), whereas the median time 
before second substitution was 10 months (IQR 6 – 15) from the time of the first substitution. 
The median time before switching was 31 months (IQR 24 - 39). A total of 31% of the study 
subjects underwent a substitution once, whereas 1.8% underwent a second substitution. Only 
six (1.2%) patients switched to a second line treatment after the modification of the treatment. 
The most commonly recorded reason for the first substitution was toxicity (19%). As in other 
studies, stavudine (D4T), nevirapine (NVP) and efavirenz (EFV) were the ARVs associated 
with most of the recorded toxicities. High viral load (50%) was the most reported reason for 
switching. In almost half of the substitution cases the reasons for substitution were not stated, 
and in a third of the switch cases the reasons for switching were not stated.  
 
Conclusion: The rate of substitution at 31% was similar to that found in other resource poor 
settings, however, the rate of switching (1.2%) was much lower than was found in similar 
settings. The main reason stated for substituting antiretrovirals was “toxicity”.  
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CHAPTER 1: INTRODUCTION 
1.1 Introduction 
The 2008 report on the global Acquired Immuno-Deficiency Syndrome (AIDS) epidemic 
from the Joint United Nations Programme on HIV/AIDS (UNAIDS) indicated that there was 
a total of 33.2 million people living with the Human Immunodeficiency Virus (HIV) in the 
year 2007 (UNAIDS, 2008). There were 2.5 million new infections and 2.1 million people 
died of AIDS in 2007. In Sub-Saharan Africa there were 1.7 million new infections with a 
total of 22.5 million infections, which represent 67%, or two thirds, of the global total. 
Globally, 50% of those that are HIV positive are women, whereas in Sub-Saharan Africa 
women make up 60% of the HIV positive population (UNAIDS, 2008).  
 
Southern Africa is the epicentre of this epidemic, with 35% of the global HIV infected people 
living in this region while it is only home to about 10% of the world’s population (UNAIDS, 
2008; SADC, 2006). Namibia is one of the Southern African countries hardest hit by the HIV 
epidemic with an estimated 230,000 people infected (MoHSS, 2004). Approximately 80,000 
of these infected people require antiretroviral treatment (ART) (MoHSS, 2007). 
 
In recognition of the above-mentioned, and the advances made in treating HIV infected 
people in other parts of the world, Namibia started providing Highly Active Antiretroviral 
Therapy (HAART) in 2002, as a pilot project at Katutura and Oshakati Intermediate 
Hospitals. HAART is characterised by the provision of at least three antiretroviral medicines 
(ARVs) to a HIV infected person (MoHSS, 2003). Based on the lessons learned from this 
pilot project, Namibia developed national guidelines for the use of antiretrovirals (ARVs). 
(MoHSS, 2003) 
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ARVs are divided in three major classes, based on their action on the HI-virus, namely: 
• Nucleoside Reverse Transcriptase Inhibitors (NRTIs); 
• Non Nucleoside Reverse Transcriptase Inhibitors (NNRTIs); and  
• Protease Inhibitors (PIs). 
The Namibian HAART is based on the backbone of NRTIs with a NNRTI and/or a PI. 
HAART consists of at least three ARVs made up of 2 NRTI and 1 NNRTI and/or 1 PI. 
Treatment regimens without a PI are classified as first line, whereas the ones that contain a PI 
are classified as second line (MoHSS, 2003).  
 
According to the Namibian ART guidelines, patients must meet the criteria indicated in the 
guidelines to qualify for HAART (MoHSS, 2003). These criteria are put in place to ensure 
that the patients are committed to lifelong treatment with ARVs, thereby reducing the number 
of defaulters and consequently the development of drug resistance. According to the 2003 
guideline, patients would be started on HAART if they had the following: WHO stage IV 
HIV disease (clinical AIDS), irrespective of CD4 cell count; or WHO stages I, II and III HIV 
disease, with a CD4 cell count of below 200 cells/mm3. In addition, before a patient is put on 
treatment, the patient must meet the following criteria: have lived at a fixed address for the 
past three months; have ready access to a designated treatment centre; have identified 
someone to serve as treatment supporter; and must be committed to long term treatment.  
 
In response to the WHO’s 3x5 strategy, which was aimed at getting 3 million HIV infected 
people in middle and lower income countries on antiretroviral therapy by the year 2005, 
Namibia rolled out the ART programme to all state hospitals country wide in 2003. By the 
end of 2007 approximately 38,046 (66%) people were on HAART (MoHSS, 2008).  
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The effectiveness of HAART in reducing morbidity and mortality has been shown in both 
industrialised (Palella et al., 1998; Berry et al., 2001) and resource limited settings (Wester, et 
al., 2005; Ivers, Kendrick and Doucette, 2005). Several studies have demonstrated, especially 
in clinical trials in industrialised countries, that long time exposure to ARVs is associated 
with adverse reactions or toxicities (Moyle, 1999; Kimm et al., 2007; Murphy, 2007).  A 
South African study assessing the adverse drug reactions in adult medical inpatients, in a 
hospital serving a community with high HIV/AIDS prevalence, found that antiretrovirals 
were the commonest class of drugs causing adverse reactions (Metha et al., 2007). Other 
studies in resource poor settings such as Malawi, Senegal and South Africa, also found that 
toxicities were the commonest reason for treatment modification (Jahn et al., 2008; Etard et 
al., 2006; Suleman and Ramkissoon, 2008). Studies have also indicated that such toxicities, 
coupled with inconveniences, such as high pill burden, dosing and dietary restrictions, affect 
adherence to these effective drugs and thus may render them ineffective (Moyle, 2003; 
Clayden, 2006).  
 
In order to address such negative effects, clinicians and their patients are required to modify 
such therapies in order to reduce or eliminate the offending medicines (Wilken, Glesby, and 
Gulick, 2006). Substitution means the changing of one or two medicines within the first or 
second line regimen, whereas switching refers to the changing from a first line regimen to a 
second line regimen. Understanding the extent and reasons for substituting and switching 
ARVs, and which toxicity is associated with which antiretroviral could allow providers to 
target those toxicities, or be cautious with the use of toxicity-associated antiretrovirals to 
reduce interruption or discontinuation of antiretroviral therapy. 
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In Namibia the number of people on antiretrovirals has increased with the scaling up of 
antiretroviral therapy services. When the scaling up process started in 2003 less than 3% of 
the people requiring treatment were on treatment. By the end 2007, 66% (38,046) were on 
antiretroviral treatment (MoHSS, 2008). It is further projected that by the end of 2013, 80% 
of those requiring treatment (84,000) will be on antiretroviral treatment. These figures 
indicate that large numbers of people will be exposed to ARVs. The Katutura Intermediate 
Hospital (KIH) is one of the three intermediate hospitals in the country, and being situated in 
the capital city, Windhoek, it receives referrals from the other two intermediate hospitals as 
well as the district hospitals. As one of the ART pilot sites, the Katutura Intermediate 
Hospital has one of the highest numbers (12%) of people on antiretrovirals compared to all 
other sites. This study intended to describe the extent and reasons for substituting and 
switching Highly Active Antiretroviral Therapy at the Katutura Intermediate Hospital. 
 
1.2. Aim and objectives 
1.2.1. Aim 
To describe the extent and reasons for substituting and switching highly active antiretroviral 
therapy at the Katutura Intermediate Hospital (KIH) in Windhoek, Namibia. 
 
1.2.2. Objectives 
1. To measure the extent of substitution of antiretrovirals in the provision of HAART 
at KIH. 
2. To measure the extent of switching from the first line ARVs to second line ARVs 
in the provision of HAART at KIH. 
3. To describe the stated reasons for substituting and switching ARVs in the 
provision of HAART at KIH. 
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CHAPTER 2: LITERATURE REVIEW 
This chapter will consist of two sections. The first section will clarify terms and concept 
used, whereas the second section will highlight relevant literature on the subject matter. 
 
2.1. Definition of terms and concepts 
Antiretroviral drugs  
These are medications that are used in the treatment of infections caused by Human 
Immunodeficiency Virus.  There are different classes of antiretroviral drugs and they act at 
different stages of the Human Immunodeficiency Virus life cycle (WHO 2006a:24). (See 
Table 2) 
 
HAART regimen 
HAART stands for highly active antiretroviral therapy, which refers to the taking of three or 
more antiretroviral drugs for the treatment of HIV infection. 
 
1st line treatment regimens 
REGIMEN (ART guideline 2003) REGIMEN (ART guideline 2007) 
NVP/D4T/3TC; NVP/AZT/3TC; NVP/AZT/ddI; 
(NVP/D4T/ddI) 
NVP/D4T/3TC; NVP/AZT/3TC  
EFV/D4T/3TC; EFV/AZT/3TC; EFV/AZT/ddI; 
(EFV/D4T/ddI) 
EFV/D4T/3TC; EFV/AZT/3TC 
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2nd line treatment regimens 
REGIMEN (ART guideline 2003) REGIMEN (ART guideline 2007) 
IDV/r/D4T/3TC; IDV/r/AZT/3TC; 
IDV/r/AZT/ddI; (IDV/r/D4T/ddI) 
 
LPV/r/D4T/3TC; LPV/r/AZT/3TC; 
LPV/r/AZT/ddI; (LPV/r/D4T/ddI) 
LPV/r/AZT/TDF/3TC; LPV/r/AZT/3TC/ddI; 
LPV/r/ABC/ddI 
 
CD4+ T-cell (T-lymphocytes bearing the CD4 receptor) count  
This is one of the useful and reliable methods to assess if a Human Immunodeficiency Virus 
positive patient should start antiretroviral therapy, as well as assessing the effectiveness of 
antiretroviral therapy. According to the Namibian antiretroviral therapy guideline of 2003 (as 
well as the guideline for 2007) treatment is started once a patient’s CD4 cell count is ≤200 
cells/mm3.  
 
Modification 
Modification is defined as substituting antiretrovirals or switching antiretroviral therapy  
 
Substitution 
Substitution is defined as replacing one antiretroviral medicine in antiretroviral therapy with 
another antiretroviral medicine of the same class, e.g. replacing one Nucleoside Reverse 
Transcriptase Inhibitor antiretroviral with another Nucleoside Reverse Transcriptase Inhibitor 
antiretroviral.  
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Switching 
Switching is defined as replacing first line antiretroviral medicines with second line 
antiretroviral medicines.  
 
Viral load 
Viral load is a measure of the severity of a viral infection, and can be calculated by estimating 
the plasma level (quantity) of human immunodeficiency virus (HIV) ribonucleic acid (RNA). 
It is measured as RNA copies/ml of blood plasma. 
 
2.2. Relevant literature 
The human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency 
syndrome (AIDS), replicates continuously in CD4 cells causing their depletion and 
predisposing the patient to opportunistic infections and tumours. There is currently no cure 
for HIV infection, only ways to control it and attempt to keep it from progressing into AIDS. 
A key strategy in fighting the global epidemic of HIV/AIDS has been the development of 
antiretroviral medicines. Antiretrovirals act by slowing down the reproduction rate of the 
human immuno-deficiency virus.  There are three classes of antiretrovirals named after their 
mechanism of action, as indicated in Table 1 below. 
Table 1: Classes of antiretroviral (adapted from MoHSS, 2003)  
Antiretroviral class Antiretroviral 
Nucleoside reverse transcriptase inhibitors 
(NRTI) 
zidovudine, stavudine, didanosine, 
zalcitabine, lamivudine, abacavir, 
emtricitabine 
Non-nucleoside reverse transcriptase 
inhibitors (NNRTI) 
nevirapine, efavirenz 
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Protease inhibitors (PI) saquinavir, indinavir, ritonavir, amprenavir, 
lopinavir-ritonavir, atazanavir 
*underlined antiretrovirals are in the MoHSS guidelines for antiretroviral therapy of 2003 
Nucleoside reverse transcriptase inhibitors work by halting the multiplication of the virus by 
stopping the elongation of the new DNA chain. Non-nucleoside reverse transcriptase 
inhibitors bind directly to the reverse transcriptase enzyme, thereby interfering with its 
activity. The difference between the mechanism of action of NNRTIs and NRTIs is that 
NRTIs competes with the naturally occurring deoxynucleotides needed to synthesize the viral 
DNA, whereas NNRTIs binds at a different site on the enzyme and thereby inhibits the 
movement of protein domains needed to carry out the process of DNA synthesis. Protease 
inhibitors block the enzyme protease which is necessary for final processing and thereby 
prevents maturation into an infectious virus.  
 
Highly Active Antiretroviral Therapy (HAART), which is the combined use of 
antiretrovirals, prevents the HIV from spreading in the body at different stages of its 
development process and thereby avoids development of resistant viral strains, delays clinical 
progression and diminishes mortality (Carpenter et al., 2000). HAART consist of at least 
three antiretrovirals of at least two different classes (MoHSS, 2007). There are first line and 
second line treatment regimens of HAART in terms of the guidelines for antiretroviral 
treatment (MoHSS, 2003). The second line treatment regimens contain protease inhibitors 
and are mainly reserved for those patients that fail or do not respond well to first line 
treatment regimens. In 2007 Namibia introduced a second edition of the National Guidelines 
for Antiretroviral Therapy. The second edition was necessitated by experiences from the first 
editions and new developments in clinical practise of antiretroviral therapy provision. The 
second edition of the guideline have several changes such as the introduction of new 
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antiretrovirals, e. g. tenofovir, abacavir, to increase the number of treatment options available 
to clinicians. Another change is the increased baseline level of CD4 cell count, from 200 to 
250 cells/mm3, for pregnant women to start ART.  
 
2.2.1. Improved survival with antiretrovirals 
The advent of ARVs has reduced the rate of morbidity and mortality in people infected with 
HIV in both developed and developing countries (Palella et al., 1998; Hogg et al., 1998; 
Nkhoma et al., 2008). In their study Palella et al found that the rate of mortality was reduced, 
even for patients with a low CD4 count (≤50 mm3), with the increase in intensity of ART (the 
use of a combination ARVs).  A Botswana study also found that the rate of survival of HIV 
infected patients increased with the use of ART (Wester et al., 2005). A study by Emery et 
al., (2008) that compared two groups of patients, those who were either ART naïve or did not 
receive ART for at least 6 months and those who were continuously on ART, found that the 
risk of opportunistic diseases and progression to AIDS was reduced by early ART use rather 
than deferred ART use. This was further confirmed by Berry et al., (2001) that indicated that 
initiation of combination antiretroviral therapy at the diagnosis of HIV produced significant 
virologic, immunologic and clinic benefits to patients. Dragsted et al., (2004) also found that 
the risk of immunological failure, in patients that respond well on their HAART treatment, 
diminished the longer they stayed on an effective treatment.  
 
In many resource poor countries, ART is only started once the CD4 cell count ≤200 
cells/mm3 in asymptomatic patients. However, several studies (Sterling et al., 2003; Lau, 
Gange and Moore, 2007) have indicated that the chances of survival were increased if ART 
was started earlier, i.e. at CD4 cell counts of >200 cells/mm3. In their study Sterling et al 
(2003) found that the risk of clinical disease progression was high among patients who 
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initiate therapy at CD4 cell count <200 cells/mm3. In a Botswana study it was found that the 
risk of mortality was 3.2 times more for those patients who started ART with a CD4 count 
≤50 mm3 than those who started with a CD4 count >50 mm3. Stringer et al., (2006) in 
Zambia, further confirmed that starting ART at CD4 count >200 mm3 increases the chances 
of survival as compared to starting with lower CD4 cell count.  
 
Starting treatment at CD4 cell counts >200 mm3 would have implications for patients, as they 
would be required to start antiretroviral therapy earlier. It would expose patients that are put 
on toxic antiretrovirals to the effects of these antiretrovirals very early and for much longer 
times, compared to if they had waited for the CD4 cell count to drop. Governments in 
resource poor settings would also be stretched for resources. If patients should start at higher 
CD4 cell counts than what is in the current guidelines (≤200 cells/mm3), then this would 
mean more patients would be on treatment and this would require more human and financial 
resources (including facilities) to manage the antiretroviral treatment programme.   
 
Evidence from studies indicates that there is a need to control opportunistic diseases in order 
to improve prognosis of HIV infected patients (Pallela et al., 1998; Lau, Gange and Moore, 
2007). Pallela et al., found that there is a corresponding decline in morbidity, especially of the 
most common opportunistic diseases such as P. carinii pneumonia, M. avium complex 
disease and cytomegalovirus retinitis, with the increased intensity of the ART. These findings 
further confirmed that viral load is inversely proportional to ART intensity, with patients on 
no ART having the highest viral load and those on combination ART containing a PI having 
the lowest viral load (Pallela et al., 1998). In their study that compared risk of non-AIDS 
related mortality to that of AIDS related mortality, Lau, Gange and Moore (2007), found that 
AIDS related mortality was much higher than non-AIDS related mortality in patients with 
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CD4 counts equal to or less than 200 cells/mm3. However, this study also found that the 
overall AIDS-related mortality decreased with the increased use of HAART.  
 
2.2.2. Adherence to antiretrovirals 
The provision of ARVs by means of HAART reduces the viral load and thereby reduces the 
progression of HIV infection into AIDS (WHO, 2003). In order to prevent progression of the 
disease, patients must maintain an undetectable level of the virus, which requires them to 
maintain a very high adherence level. Adherence to ARV medicines is a key determinant of 
the success of HAART (MoHSS, 2007). Poor adherence may lead to virological failure, 
development of resistance to the medicines with the resulting poor clinical outcome of the 
treatment. In order to be able to suppress the viral load to levels less than 400 copies/ml, the 
patients must be more than 95% adherent to their ARV medications (Chesney, 2003). A study 
by Brigido et al., (2001), in Brazil, found that the risk of both development and death to 
AIDS increased with lower adherence levels. The less adherent the patient was on the 
medications, the greater the inability to suppress the viral replication. 
 
Adherence to antiretrovirals is one of the many challenges patients face in maintaining 
successful antiretroviral therapy. In addition, antiretrovirals can also cause adverse effects 
that in turn may affect patients’ adherence in the long term. Therefore, there is need to 
prepare patients for the implications of being on HAART before they are started on 
treatment. 
 
2.2.3. Antiretroviral toxicities 
Aniretrovirals, like any other drugs, are not without potential toxicities. Some toxicities are 
mild and easily manageable, while some warrant stopping therapy. Since there is no cure for 
HIV infection, patients need to take their HAART treatment lifelong. This long term 
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exposure of patients to ARVs may have a negative effect on the patient, that is, the patient 
gets exposed to adverse effects of the antiretroviral medicines (Moyle, 2003). There are class-
wide side effects for NRTIs, NNRTI and PIs as indicated in Table 2 (Powderly, 2002; 
Shibuyama et al., 2006). 
 
Table 2: Class-wide toxicities of antiretrovirals (adapted from Shibuyama et al., 2006) 
Class of antiretroviral Toxicities 
Nucleoside/nucleotide 
reverse transcriptase 
inhibitors (NRTI) 
 
Anaemia, neutropenia, lactic acidosis, hepatic toxicity, 
pancreatitis, peripheral neuropathy, lipoatrophy, myopathy, 
metabolic side effects 
Non-nucleoside transcriptase 
inhibitors (NNRTI) 
 
Rash (hypersensitivity), hepatic toxicity, central nervous 
system reactions  
Protease inhibitors (PI) Lipid and glucose abnormalities, nephrolithiasis, skin 
changes 
 
 
The negative effect of long term use of antiretrovirals has been shown in clinical trials and 
general clinical practise in both developing and developed country settings. In a Uganda 
study by Forna et al., (2007), in which patients were treated with stavudine, lamivudine and 
nevirapine or efaverenz, toxicities developed in 40% of the patients; 36% of the patients 
developed peripheral neuropathy, of which 9% was severe. The other toxicities reported 
included rash (6%), of which 2% was severe; hypersensitivity reaction (2%); acute hepatitis, 
anaemia, acute pancreatitis, and lactic acidosis all of which constituted less than 0.5%. An 
Italian cohort study by Monforte et al., (2000), found that 36.2% of the patients discontinued 
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their initial HAART regimen. The reasons cited for these discontinuations were toxicity 
(21.1%), regimen failure (5.1%), non-adherence (7.1%) and other reasons (2.9%) (Monforte 
et al., 2000). According to Calza, Manfredi and Chiodo (2003), protease inhibitor (PI) 
containing treatments are associated with a rapid increase in plasma lipid concentrations in 
70% to 80% of the patients. PI regimens are also associated with fat redistribution and 
lipodystrophy syndrome. Patients on HAART containing the PIs indinavir and ritonavir were 
more likely to discontinue treatment compared to those with regimens containing the PI, 
saquinavir.  
 
An Indian study that assessed the clinically significant toxicities of long term, fixed dose 
generic HAART, found that rash (15.2%) and peripheral neuropathy (9%) were the most 
common toxicities (Kumarasamy et al., 2008). Other clinically significant toxicities were 
anaemia (5.4%) and hepatitis (3.5%). In this study women were more likely to experience 
lactic acidosis, whereas the incidence of immune reconstitution syndrome was higher in men. 
Hawkins et al., (2007) in their study of an urban Kenyan population found that 26.5% of the 
patients experienced ART-related toxicities. Neuropathy was the highest reported toxicity at 
20.7% of the observed toxicities. Schramm et al., (2008) reported that 97% of patients in their 
study were diagnosed with ARV related toxicities of which 19% were severe. The most 
frequent diagnoses were: lipodystrophy (63%), hypertriglyceridemia (41%), asthenia (32%) 
and increased liver enzymes (27%). Suleman and Ramkissoon (2008) in their public sector 
antiretroviral services study in South Africa found that the most common side effects for 
patients on first line HAART was peripheral neuropathy (36%). However a study by Arenas-
Pinto et al., (2008) has shown that peripheral neuropathy is experienced shortly after ART 
exposure. This could indicate that the development of peripheral neuropathy with long term 
use of ART is limited to subgroups rather than being generalised.   
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Although there are class-wide toxicities associated with ARVs, particular ARVs are 
associated with a higher incidence of a particular toxicity compared to others in the same 
class (WHO, 2008; MoHSS, 2008), as indicated in the Table 3 below. 
 
Table 3: Toxicities mostly associated with specific antiretrovirals (adapted from 
Shibuyama et al., 2006) 
Class Antiretroviral Toxicities 
Nucleoside/nucleotide 
reverse transcriptase 
inhibitors (NRTI) 
zidovudine (AZT) Anaemia, neutropenia, myopathy  
stavudine (D4T) 
Peripheral neuropathy, 
lipoatrophy, lactic acidosis 
didonasine (ddI) Pacreatitis, peripheral neuropathy 
Non-nucleoside 
transcriptase inhibitors 
(NNRTI) 
nevirapine (NVP) 
Rash (hypersensitivity), hepatic 
toxicity 
efavirenz (EFV) 
Central nervous system reactions, 
possible teratogenecity 
Protease inhibitors (PI) 
indinavir (IDV) Nephrolithiasis, skin changes 
ritonavir (RTV) Lipid and glucose abnormalities 
 
 A study by Law et al., (2003) found that nevirapine was associated with a higher incidence 
of severe hepatoxicity in patients receiving NNRTI containing regimens. A Spanish study 
also found that 9% of the patients discontinued nevirapine because of either rash or 
hepatotoxicity (Martinez et al., 2001). A study assessing the antiretroviral-associated toxicity 
in Mozambican pregnant women found that severe hepatoxicity was more common in those 
receiving a nevirapine-containing HAART and a CD4 cell count of ≥250 cells/mm3 (Jamisse 
et al., 2007). Several studies also found that Hepatitis virus B and C co-infection, female 
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gender and high CD4 cell count are risk factors for NNRTI associated toxicities, which are 
mainly rash and hepato-toxicity (van Leth et al., 2005; Kappelhoff et al., 2005; van 
Schalkwyk et al., 2008).    
 
Brinkman et al., (1998) indicated that nucleoside analogues cause mitochondrial DNA 
toxicity, which in turn result in the clinically observed symptoms and signs of these ARVs. 
According to Brinkman et al. (1998), long term use of AZT is associated with myopathy and 
bone-marrow toxicity (anaemia), whereas long term use of D4T is associated with 
neuropathy, pancreatitis, hepatic steatosis and lactic acidosis. Murphy et al., (2007) further 
confirmed that mitochondrial toxicity is responsible for the earlier mentioned adverse effects 
as well as lipodystrophy caused by NRTIs such as D4T and DDI.  
 
Some studies have indicated that exposure to D4T, female gender and body mass index 
(BMI) greater than 25 are risk factors for lactic acidosis (John et al., 2001; Wester et al., 
2007; Geddes et al., 2006). It was further shown that replacing the offending ARVs with less 
potent mitochondrial inhibitors reduces or even reverses the adverse effect (Lonergan, Barber 
and Mathews, 2003). 
 
A Rwandan study found that the prevalence of lipodystrophy was more than three times 
higher in D4T containing regimen compared to AZT containing regimen. Other studies also 
found that long term use of D4T is a risk factor for lipodystrophy (van Griensven et al., 2007; 
Mauss et al., 2002; Saint-Marc et al., 1999; Joly et al., 2002; Chariylertsak et al., 2008).  
McComsey et al., (2008) have shown that the mitochondrial RNA and DNA alterations in 
subcutaneous fat tissue of HIV positive subjects with lipoatrophy are linked to ART and not 
HIV infection. This was confirmed by the fact that the adverse effect improved when the 
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offending ARV was replaced by less mitochondrial toxic antiretrovirals (Domingo et al., 
2004; Garcia-Benayas et al., 2003; McComsey et al., 2005; Llibre et al., 2006; Martinez et 
al., 2008).  
 
Several studies also showed that long term use of D4T is associated with high prevalence of 
peripheral neuropathy (Konchalard and Wangphonpattanasiri, 2007; Scarsella et al., 2002; 
Laurent et al., 2008; Canestri et al., 2007). As with all mitochondrial toxic ARVs the adverse 
event is reduced or reverse once mitochondrial toxic ARV is substituted with a mitochondrial 
less toxic ARV (Makinson et al., 2008).  
 
In most of the studies toxicities did not necessitate the termination of the treatment, toxicities 
were managed by substituting the offending medicine or by treating the toxicity. In general, 
the rate of discontinuation due to toxicities reduced the longer the patients were on the 
treatment (Monforte et al., 2000).  
 
2.2.4. Modifying Antiretrovirals 
There are several options available for clinicians to manage antiretroviral (ARV) toxicities, 
these include substituting an offending drug with another within the same group, switching to 
a second line regimen, treating the toxicity, interrupting the treatment for certain periods - so 
called “treatment holidays” or discontinuing the treatment. In terms of the 2003 Namibian 
Antiretroviral therapy guideline, antiretroviral therapy (ART) may be changed due to toxicity 
or treatment failure. In the case of a toxicity associated with an ARV, the offending ARV 
must be replaced with another ARV that does not have the toxicity or is less toxic.  
 
2.2.4.1. Substitution 
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Substitution is one of the strategies available to clinician to manage antiretroviral toxicities. It 
is defined as replacing one antiretroviral medicine in antiretroviral therapy with another 
antiretroviral medicine of the same class, e.g. replacing one nucleoside reverse transcriptase 
inhibitor antiretroviral with another nucleoside reverse transcriptase inhibitor antiretroviral.  
A Botswana study assessing the response to Highly Active Antiretroviral Therapy (HAART), 
found that there was a 32.2% rate of switching due to toxicities to drugs (Wester et al., 2005). 
In a clinical trial analysis of an United Kingdom study by Mocroft et al., (2001), 64.4% of the 
patients modified (defined as stopping at least one of the ARVs in the regimen) their HAART 
due to toxicities or patient choice. Mocroft et al., further found that patients that started more 
than three ARVs were more likely to modify their regimen, as were those that had regimens 
containing ritonavir (Mocroft et al., 2001). In an Indian study, 20% of the patients modified 
(defined as any alteration of one or more components of the regimen) their first line regimen. 
The reasons for modification were adverse effects (64%), cost (19%) and treatment failure 
(14%) (Kumarasamy et al., 2006). 
 
A Zambian study assessing the effectiveness of their ART programme, found that there was a 
40% switching of ARVs due to toxicities (Stringer et al., 2006). An urban outpatient cohort 
study in the United States of America found that 61% of the patients changed or discontinued 
their initial treatment, primarily because of adverse events (24%) (O’Brien et al., 2003). 
Cesar et al., (2008) in their study in the Caribbean and Latin America found that 36% of the 
patients switched ARVs and in 58% of the cases the given reason was toxicities. In a Cape 
Town based South African study by Boulle et al., (2007) up to 28% of the patients had at 
least one ARV substitution in a period of 3 years. A Malawian survey found that 2.9% 
patients substituted at least one antiretroviral (ARV) of their first line treatment. The recorded 
reasons for these substitutions were skin rashes (45.6%) and peripheral neuropathy (44%). 
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The decision to substitute an antiretroviral depends on the ability of the clinician to associate 
the toxicity with a particular antiretroviral as well as the severity of the toxicity. In general 
mild toxicities do not require substitution, but can be managed symptomatically. Mild 
toxicities are those that do not have symptoms causing an inability to perform usual social 
and functional activities (Sabundayo et al., 2006).  
 
2.2.4.2. Switching 
Switching is an option available to clinicians to “rescue” a patient from a failing regimen. It 
is defined as modifying a treatment from a first line regimen to second line regimen. 
According to WHO, determining treatment failure can be done in three ways: 1) clinically, by 
disease progression and WHO staging; 2) immunologically, using CD4 cell counts over time 
and 3) virologically, by measuring plasma viral loads (WHO, 2006). In resource poor settings 
laboratory equipment required for immunological and virological assessment are not usually 
available due to cost. Therefore, clinicians in resource poor settings mainly rely on disease 
progression and WHO staging, which might be “too late” for the patient. WHO in its 2006 
revision of the antiretroviral therapy recommendations indicated that the timing of switching 
is critical; if made too early it depletes available options and alternatively if it is made too late 
the prognosis of the patient is affected negatively.  
 
The TREAT Asia HIV Observational Database (TAHOD) study found that 39% of the 
patients changed their first line treatment and from those 6% changed to second line 
treatments (Srasuebkul et al., 2007). In a South African study looking at the cost-
effectiveness of ART in Khayelistsha, it was found that no patients changed their regimen 
during the first six months on treatment. However, at 48 months 16% had switched (Clearly, 
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McIntyre and Boulle, 2006). Coetzee et al., (2004) found that at 24 months follow-up 8.7% of 
the patients of their Khayelitsha (South Africa) study have changed to a second line regimen. 
Coetzee et al., (2004) further found that 15.1% of patients changed their treatment due to 
toxicities or contraindications, and 8.4% due to toxicities alone. 
 
2.2.4.3. Discontinuation 
Although discontinuing the ART is not desirable, it has been reported to occur mainly due to 
drug toxicities. Discontinuation is defined as stopping all antiretrovirals at once. If the 
toxicity is life-threatening there is a need to discontinue antiretroviral therapy until the patient 
has stabilised (WHO, 2006). However, there are concerns with this strategy because NNRTIs 
have a longer half life compared to NRTIs and so this may result in patients receiving mono-
therapy for a period of time, which in turn may result in development of resistance to 
NNRTIs. However, WHO recommends discontinuation because benefits outweigh the risk of 
resistance development to NNRTIs. In a clinical trial analysis of an United Kingdom study by 
Mocroft et al., (2001), 26% discontinued (defined as simultaneously stopping all ARVs) their 
HAART regimen within the first year of therapy. In a Ugandan study assessing the 
discontinuation and modification of HAART, 13.7% patients discontinued their initial 
treatment (Kiguba et al., 2007).  
 
The rate of modification, in the first year of treatment, is in general much lower in studies in 
resource poor settings compared to studies in developed countries. The reason for the low 
rate of substitutions could be that in resource poor settings the clinicians are working with a 
limited formulary, as alternatives within the same drug classes may not be available due to 
cost. The reason for the low rate of switching in resource poor setting could be that the health 
professionals in these settings are trying to preserve the available second line therapies. 
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Therefore, they try to keep the patients on the first line treatment as long as possible (WHO, 
2006). 
 
Apart from aforementioned differences all studies indicated adverse reactions as the main 
reason for changing therapy. This was followed by treatment failure in studies in the 
developed country setting, whereas cost was the second cause of change in the some resource 
poor settings. In developed countries ART is generally provided free of charge or covered by 
private insurance, but in many resource-poor setting patients have to pay for their 
antiretroviral therapy medicines out of their pockets. This is prohibitive for those in resource 
poor settings, especially with regard to the high prices of newer and less toxic ARVs. 
However, the new move to assist with rolling out of ART services in resource poor settings 
has lead to reduction of ARV prices and donor funding of some antiretrovirals. Although 
these factors have increased the uptake of antiretroviral therapy, other factors such as stigma, 
lack of availability of qualified health personnel, infrastructure and laboratory monitoring still 
negatively impact on access to HAART in resource poor settings (Stringer et al., 2006; 
Carmody et al., 2003).  
 
The WHO report in its “Towards Universal Access” strategy indicated that a large number of 
patients have been put on antiretrovirals (ARVs), especially in resource poor countries 
(WHO, 2008). According to this reports there were 2 million people on ARVs at the start of 
this strategy in 2005, this figure has increased to about 3 million people on ARV treatment at 
the end of 2007. These figures indicate that many more people will be exposed to ARVs. 
Namibia has also scaled up the provision of antiretroviral therapy considerably and by the 
end of 2007 there were approximately 37,000 people on antiretroviral therapy, compared to 
less than 10,000 in 2005. As more Namibian patients are put on HAART, there is need to 
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determine the effect of long term antiretroviral drug use on these patients, so that clinicians 
can optimally manage their patients on HAART. 
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CHAPTER 3: METHODOLOGY 
3.1. Study Design 
A descriptive retrospective case series study was chosen in which medical records were 
reviewed to determine the extent and reasons for substituting and switching HAART. The 
researcher chose this method, because the required information was readily available and it 
involved minimal resources. The researcher did not have any sponsors and had also work 
commitments. Therefore, this method suited the researcher as it enabled him to meet his work 
commitments and also do the research. 
 
3.2. Study Setting 
This study was carried at an urban intermediate hospital in Namibia. The Katutura 
Intermediate Hospital is an 800 bed hospital that serves as a referral hospital. In addition to 
the general services available at other district hospitals, it also offers specialist services such 
as gynaecology, urology, ophthalmology, orthopaedics and ENT. This intermediate hospital 
commenced the provision of antiretroviral therapy (ART) as one of the pilot centres in 
Namibia in 2002 and ART was later rolled out country wide from 2004, based on lessons 
learned from the pilot programme. The number of people put on antiretrovirals increased with 
the scaling up of antiretroviral therapy services. When the scaling up process started in 2003 
less than 3% of the people requiring treatment were on treatment. By the end 2007, 66% 
(38,046) were on antiretroviral treatment (MoHSS, 2008). Of these patients about 12% are 
receiving their treatment at KIH. It is further projected that by the end of 2013, 80% of those 
requiring treatment (84,000) will be on antiretroviral treatment.  
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3.3. Study Population 
The study population was all adults (18 years and above) that started on Highly Active 
Antiretroviral Therapy (HAART) between 1st January 2002 – 31st December 2006 at the KIH. 
The only inclusion criterion was that the patients must have had at least one follow-up visit 
subsequent to commencing HAART.  
 
3.4. Study Sample  
The KIH has an enrolment rate of approximately 60 patients per month on HAART and it 
was found that 3477 patients were enrolled on ART between 1 January 2002 and 31 
December 2006. The sample size was calculated with the assistance of Epi Info version 6 
using the following assumptions: 
• There are several variables that will be measured and thus the researcher will use the 
extent of switching from 1st line to 2nd ART as the determining variable, because it 
has the lowest expected rate of 15% (Clearly, McIntyre and Boulle, 2006). 
• The researcher would prefer the range of the true value to be ±3% from the expected 
value. 
• 95% confidence interval 
The calculated sample size for the population of 3477 was 471, but the researcher used the 
sample size of 500 to accommodate for records that were incomplete and would require 
skipping/disregarding certain selected files. The researcher randomly selected 500 records of 
the adult patients that enrolled for ART during the period of 2002 – 2006. Simple random 
sampling was used to get the study sample for this research project. Since the inception of the 
ART programme, patient files have been kept for all the patients enrolled for treatment. 
These files were allocated unique patient numbers, which were in chronological order that 
were used throughout the health system and not the patient names. The researcher used these 
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numbers and fed them in the Moonstat® software to generate the random numbers for the 
defined sample size. The selected files were then numbered serially, and these numbers were 
then used for research purposes. The researcher was unable to get the required sample size 
with the first run of the random numbers and thus had to repeat this exercise three times. At 
the end of the third cycle the researcher had 535 records. The first 500 hundred records were 
then enter into Epi Info version 6 (2005) and checked for duplicate numbers. Sixteen (16) 
duplicate numbers were found and replaced with non-duplicate numbers from the remaining 
35 records. 
 
3.5. Data Collection  
A pre-piloted data collection tool (Appendix A) was used to collect the data. The following 
information was collected: baseline CD4 count, weight, initial ARVs, first and second ARV 
substitutions, first ART switch and the reasons for substituting ARVs or switching ART 
during the indicated period. A pilot of 15 patient files was carried out at the Windhoek 
Central Hospital. Windhoek Central Hospital is a similar type of hospital to that of Katutura 
Intermediate Hospital (KIH) making it a suitable setting for piloting the data collection tool. 
Both the Windhoek Central Hospital and KIH are higher level health facilities compared to 
district hospitals. At higher level facilities, specialists and consultants, as well as laboratory 
equipment, are readily available. Therefore, piloting the data collection tool at such a facility 
was appropriate. Minor adjustments were made to the data collection tool after the pilot to 
collect data that was not included initially in the tool, such as the latest weight, latest CD4 
and time on treatment. 
 
The ART clinic of KIH retains all the patient files in a locked filing room. The files were 
stored in locked metal cabinets that are chronologically numbered. Each file had records of 
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one patient that consisted of prescription book, clinician’s note booklet and all laboratory 
results of the patient. Access to the files was restricted to data clerks and nurses based at the 
ART clinic. The researcher accessed the patient files with the permission of the Senior 
Medical Superintendent of the hospital. This permission was granted once the research study 
protocol was accepted by the Ministry of Health and Social Services (MoHSS), which also 
included permission to conduct the study by the Permanent secretary of the MoHSS. The 
researcher collected the data himself, thus there was no need to train data collectors. 
However, two data clerks that were used to counter-check the collected data were trained on 
what information to look for in the patient file to check the correctness of the collected data 
in the data collection tool. This was done by simulation, where the researcher would collect 
data from the patient files and the data clerks would counter-check the collected data from the 
file from where it was collected in the presence of the researcher. Only when the clerks were 
able to ensure a 100% counter check were the clerks “recruited” to do the counter checking. 
The data was collected between the 30th May 2008 and 30th June 2008. 
 
3.6. Data Management and Analysis 
The researcher collected the data himself by transcribing what the clinicians had written in 
the patient’s file to the data collection tool. The researcher made use of two data clerks, 
responsible for the filing of these files, to do a counter-check on 10% of the files, at a 
minimum of three intervals during the data collection. In other words, once the researcher had 
finished 100 data collection records, for example, then the clerk would randomly pick 10% of 
the completed data collection records, which is ten data collection records in this case. The 
clerk would then counter-check the data collected with the specific patient file for each data 
collection record. The collected data was kept in the researcher’s office in a locked cabinet. 
When the researcher was not in his office, both the office and the cabinet were locked and the 
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keys always in possession of the researcher. The collected data was entered into the computer 
for analysis, using Epi Info version 6. Data entry was checked by a colleague who is a Master 
of Public Health (MPH) student. The data was entered directly into Epi Info and when 
required the researcher would export the data to Windows Excel to perform certain analyses. 
The computer was password protected to ensure confidentiality of the data. Once entered into 
Epi Info the data was cleaned by running frequencies of the reference numbers to ensure that 
there were no double entries and scrutinized for invalid values. 
 
The data was analysed using Epi Info version 6. Since it was a case series study the results 
are presented by means of simple descriptive statistics such as frequencies, proportions, 
means (or medians where distribution is not normal) for all important variables in the data 
set.  
 
3.7. Validity and Reliability 
The issues of validity and reliability in the study were addressed in a number of ways. The 
most accurate measurements are obtained by measuring the entire population. However, due 
to lack of time, financial and material resources it was not possible to study the entire 
population. Therefore, a representative sample was drawn from the study population.  Simple 
random sampling was used to draw a representative sample from the population. This ensured 
that all possible samples have an equal probability of being selected and addressed the issue 
of selection bias (De Vos, 2002). 
 
Measurement bias was addressed by the researcher collecting all the data himself and by 
transcribing directly what the medical doctor had written in the patient’s file onto the data 
collection tool. The pre-piloted data collection tool was designed to collect only the data 
required for the study. When collecting the data the researcher made use of the two trained 
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data clerks, responsible for the filing of these files, to do a counter check on 10% of the files, 
at a minimum of three intervals of data collection. During data entry the researcher requested 
a colleague, who is also a MPH student, to counter check the entered data. Data was also 
cleaned by examining frequencies to ensure that there were no duplicate or erroneous entries.  
 
3.8. Generalisability   
As the sampling method ensured that the study sample was representative of the study 
population, that is, patients who commenced HAART at KIH between 1 January 2002 and 31 
December 2006, the results may be generalisable to this study population. However, they are 
not generalisable to the wider population on HAART throughout Namibia.  
 
3.9. Limitations 
One of the major limitations of the study was that in many cases either the reasons for 
modification of ART were not recorded in the patients’ files (‘missing’), or that the reasons 
were given in broad terms, such as ‘toxicity’. This made proper quantification of these 
parameters difficult. The study will not be able to determine causality, but might be able to 
find association. The study also excluded HAART patients who did not have a follow up visit 
recorded in their notes. Inclusion of these patients may have given a false indication that 
more patients stay on their initial therapy without any modification.  
 
 
3.10. Ethical considerations 
This study did not involve contact with human subjects. All the required data was collected 
from secondary data sources, that is, medical records. Ethical approval was obtained from the 
University of the Western Cape Ethics Committee and the Ministry of Health and Social 
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Services (Appendix B). Approval was also obtained from the Senior Medical Superintendent 
of the Katutura Intermediate Hospital for access to the patient files. As only already available 
information was transcribed from the files there was no need for clinical staff or patients to be 
present. The process of transcription of information was done mainly over the weekends and 
at other suitable times that did not adversely influence the patient flow and the work of the 
clinical staff. Confidentiality was invested in the research and no names appeared on the data 
collection tool and the researcher used patient codes to identify the patient files. The data was 
kept in a locked steel cupboard in a locked office, if not in use. The computer that was used 
for data entry and analysis was pass word protected. No names or any means of identification 
was used in the final report. The results of the study will be made available to KIH ART 
Clinic clinical staff, the management of KIH and the management of MoHSS.  
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CHAPTER 4: RESULTS 
This section describes the results of the study. This includes the demographic data, baseline 
data and other variables such as frequency of substitution and switching of antiretrovirals and 
the reported toxicities associated with the use of specific antiretrovirals.  
 
4.1. Baseline characteristics of HAART patients 
 
Table 4: Baseline characteristics of HAART patients (N= 500) 
Gender, n (%)  
Male 200 (40%) 
Female 300 (60%) 
Age (years), median (IQR) 34 (30 – 40) 
Male 38 (34 – 44) 
Female 32 (29 – 37) 
Treatment supporter, n (%)  
Yes 463 (93%) 
No 37 (7%) 
Weight (kg), median (IQR) 57 (50 – 65) 
CD4 cell count (cells/ml), median (IQR) 153 (96 – 212) 
First treatment combination, n (%)  
First line treatment 455 (91%) 
1. D4T/3TC/NVP 219 (48%) 
2. D4T/3TC/EFV 108 (24%) 
3. AZT/3TC/NVP 91 (20%) 
4. AZT/3TC/EFV 37 (8%) 
Second line treatment 31 (6%) 
1. LPV/r/3TC/D4T 13 (42%) 
2. LPV/r/3TC/AZT 18 (58%) 
Other 14 (3%) 
TDF/3TC/EFV 14 (3%) 
 
The baseline characteristics describe the health profile of the patients, who commenced on 
HAART between January 2002 and December 2006, as recorded in the patient notes when 
the patient started anti-retroviral therapy. The baseline characteristics of the study sample are 
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summarised in Table 4.  The sample was made up of 500 patients, of which 300 (60%) were 
female. The median age of the sample was 34 years (IQR 30 – 40) with the mean age being 
36 years. However, the median age of the females was lower than that of the males, being 32 
years and 38 years, respectively. The median CD4 cell count at initiation of therapy was 153 
cell/mm3 (IQR 96 – 212). More than two thirds of the patients, 359 (72%), started ART with 
a CD4 cell count of ≤200 cells/mm3 and 206 (58%) of these were females. Almost all the 
patients, 463 (93%), had treatment supporters. Overall, the median time that the individuals 
in the study sample were on treatment was 37 months with an IQR of 28 – 43 months.  
 
Most of the patients in the study sample, 91% (455), were started on one of the four first line 
antiretroviral treatment regimens as indicated in Table 4. Six percent (31) patients were 
started on a second line regimen and the remaining 3% (14) commenced on a treatment 
regimen not included in the Namibian ART treatment guideline of 2003.    
 
4.2. First substitution  
Table 5: Characteristics of HAART patients at first substitution (N=157) 
Gender, n (%)  
Male 63 (40%) 
Female 94 (60%) 
Treatment supporter, n (%)  
Yes 150 (96%) 
No 7 (4%) 
Time to 1st substitution (months), median 
(IQR) 
28 (24 – 34) 
CD4 cell count (cells/ml), median (IQR) 409 (287 – 562) 
 
Almost one third, 31% (157), of the patients in the sample underwent a first substitution of 
one or more antiretrovirals and out of these 157 patients, 60% (94) were female (See Table 
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5). The median time on treatment before substitution was 28 months (IQR 24 – 34). The 
median CD4 count at the time of first substitution was 409 cells/ml (IQR 287 – 562).  
 
Table 6: Treatment changes at first substitution (N=157) 
Initial treatment Treatment after first substitution 
First line treatment (149) First line treatment (140) Other (9) 
D4T/3TC/NVP (89) 
AZT/3TC/NVP (69) TDF/3TC/EFV (1) 
D4T/3TC/EFV (9) TDF/3TC/NVP (1) 
AZT/3TC/EFV (9)  
D4T/3TC/EFV (48) 
AZT/3TC/EFV (37) 
TDF/3TC/EFV (5) AZT/3TC/NVP (3) 
D4T/3TC/NVP (3) 
AZT/3TC/NVP (9) AZT/3TC/EFV (8) TDF/3TC/NVP (1) 
AZT/3TC/EFV (3) 
D4T/3TC/EFV (1) 
TDF/3TC/EFV (1) AZT/3TC/NVP (1) 
Second line treatment (8) First line treatment (5) Second line treatment (3) 
LPV/r/D4T/3TC (6) 
D4T/3TC/NVP (1) 
LPV/r/AZT/3TC (3) D4T/3TC/EFV (1) AZT/3TC/EFV (1) 
LPV/r/AZT/3TC (2) AZT/3TC/EFV (1) 
 
D4T/3TC/EFV (1) 
 
Out of the 89 (20%) patients on first line treatment of D4T/3TC/NVP, 87 remained on first 
line treatment and two changed to treatment not in the guideline. Of the patients on the 
D4T/3TC/EFV treatment (48), only five changed to treatment not on the guideline while the 
rest remained on first line treatment. Of the six patients on the second line treatment of 
LPV/r/D4T/3TC, three were moved back to first line treatment and the remainder were still 
on second line treatment (LPV/r/AZT/3TC). 
 
A total of 145 (92%), out of the 157 HAART patients who underwent substitution, were on 
first line antiretroviral treatment after substitution. Of those who were on first line treatment 
50% were on AZT/3TC/NVP, 39% on AZT/3TC/EFV, 8% on D4T/3TC/EFV and 3% on 
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D4T/3TC/NVP. Two percent of those who underwent first substitution were on second line 
treatment and the remaining 6% were on treatments not indicated in the ART guideline.  
 
Table 7: Number of times antiretroviral substituted at 1st substitution (N=157) 
Antiretroviral  Times substituted % 
D4T 130 75% 
NVP 27 16% 
EFV 7 4% 
AZT 4 2% 
LPV/r 5 3% 
Note: Some patients substituted more than one antiretroviral at a time, therefore the actual 
substitutions are more than  N 
 
Table 8: Substituted antiretrovirals and adverse events or toxicities at 1st substitution 
(N= 157) 
Adverse Event/Toxicity Incidence of adverse 
events/toxicities 
TOTAL 
 
D4T NVP EFV AZ
T 
LPV/
r 
 
Toxicity (unspecified) 30    1 31 (18%) 
More than 2yrs on D4T  13     13 (8%) 
Peripheral neuropathy  11 1    12 (7%) 
Lipo-dystrophy  4    1 5 (3%) 
PTB 2 10 1 1 1 15 (9%) 
Lipoatrophy  2     2 (1%) 
Gynaecomastia  2     2 (1%) 
Lactic Acidosis 1 1 (0.5%) 
Impotence 1 1    2 (1%) 
Pregnancy 1  1   2 (1%) 
Bone marrow depression  1  1  2 (1%) 
NVP hypersensitivity  1    1 (0.5%) 
Jaundice  1    1 (0.5%) 
Anaemia    1  1 (0.5%) 
Others 7 1    8 (5%) 
Missing 56 11 5 1 2 75 (43%) 
TOTAL 130 27 7 4 5 173 
 
D4T was the antiretroviral that was mostly substituted at 130 (75%) of the substitutions, 
followed by NVP 27 (16%), EFV 7 (4%) and AZT 4 (2%) respectively (Table 7). Some of 
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the patients (12) substituted more than one ARV at a time, which made the substitutions more 
than the number of patients. The most commonly reported reasons for first substitution were 
toxicities (unspecified) at 18% the highest as indicated in Table 8 (which indicates the 
number of times a toxicity was reported). Toxicity refers to any adverse advent that has not 
been specified by the clinician. The total toxicities, including unspecified toxicities, were 98 
after first substitution. In almost half, 75 (43%), of the cases reasons for substitution were not 
indicated.  
 
4.3. Second substitution 
 
Table 9: Characteristics of HAART patients at second substitution (N=9) 
Gender, n (%)  
Male 5 (56%) 
Female 4 (44%) 
Treatment supporter, n (%)  
Yes 9 (100%) 
Time to 2nd substitution (months), median 
(IQR) 10 (6 – 15) 
CD4 cell count (cells/ml) at 2nd substitution, 
median (IQR) 375 (264 – 411) 
 
A total of 9 (2%) patients in the study sample underwent a second substitution. This group 
consisted of 5 (56%) males and all had treatment supporters. The median time to second 
substitution from the first substitution was 10 months (IQR 6 – 15) and the median CD4 cell 
count at second substitution was 375cells/ml (IQR 264 – 411). 
 
Of those who underwent a second substitution, 7 (78%) were on first line treatment after the 
second substitution and two (22%) of the patients were on treatments not listed on the ART 
guideline of 2003, namely TDF/3TC/NVP and TDF/3TC/EFV, respectively. 
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Table 10: Treatment changes at second substitution (N=9) 
Initial treatment Treatment at 1st substation Treatment at 2nd substitution 
D4T/3TC/NVP (5) 
AZT/3TC/EFV (1) TDF/3TC/EFV (1)* 
D4T/3TC/EFV (3) AZT/3TC/NVP (1) AZT/3TC/EFV (2) 
AZT/3TC/NVP (1) D4T/3TC/NVP (1) 
D4T/3TC/EFV (2) AZT/3TC/EFV (1) AZT/3TC/NVP (1) TDF/3TC/EFV (1) AZT/3TC/EFV (1) 
AZT/3TC/NVP (2) AZT/3TC/EFV (1) AZT/3TC/NVP (1) TDF/3TC/NVP (1) TDF/3TC/EFV (1)* 
*Treatment not on treatment guideline 
 
Figure 1: Number of times ARV substituted at 2ndsubstitution (N=9) 
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The antiretroviral that was substituted most frequently at the second substitution was EFV, 
with four patients (36%) as indicated in Figure 1. 
The reasons recorded for the second substitutions included anaemia, TB, myopathy and 
general toxicities, however the reason was not recorded in more than a third (37%) of the 
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reported cases. D4T and EFV were the antiretrovirals associated with most recorded 
incidence of toxicities for second substitutions. 
  
4.4. Switching 
Table 11: Characteristics of HAART patients at time of switch (N=6) 
Gender, n (%)  
- Male 4 (67%) 
- Female 2 (33%) 
Treatment supporter, n (%)  
- Yes 6 (100%) 
Time to switch (months), median (IQR) 36 (28 – 39) 
CD4 cell count (cells/ml) at switch, median 
(IQR) 
182 (178 – 242) 
 
Only six patients in the study sample switched treatment and two-thirds, 67%, were males. 
The median time to switch was 31 months (IQR 24 – 39) and the median CD4 cell count at 
switching was 214 cells/ml (IQR 178 – 440). 
 
Table 12: Treatment changes at switch (N=6) 
Initial treatment Treatment after switch 
First line treatment (6) Second line treatment (1) Other (5) 
D4T/3TC/NVP (1)  LPV/r/TDF/3TC/AZT (1) 
D4T/3TC/EFV (2) LPV/r/3TC/AZT (1) LPV/r/TDF/3TC/AZT (1) 
AZT/3TC/NVP (2)  LPV/r/TDF/3TC/AZT (2) 
AZT/3TC/EFV (1)  LPV/r/IDV/r/TDF (1) 
 
A total of 6 (1.2%) patients in the study sample switched from first line to second line 
treatment. Of those who switched to second line only one (17%) switched to treatments on 
the 2003 guidelines, which is LPV/r/AZT/3TC, whereas five (83%) switched to treatments 
not listed in the guideline.  
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The most commonly reported reasons for patients switching ART was a high viral load, in 
three patients (50%). In two (33%) of the cases the reasons were not stated, whereas one 
patient (17%) was switched due to lipomastitis. 
 
In conclusion, this section highlighted the main results of this study. The results provided 
useful information on the extent and reasons for substituting and switching in this sample of 
HAART patients at the Katutura Intermediate Hospital.  
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CHAPTER 5: DISCUSSION 
This study analysed a sample of 500 patients that started anti-retroviral therapy (ART) 
between 1 January 2002 and 31 December 2006 at the Katutura Intermediate Hospital (KIH). 
It is the first study to assess the toxicities associated with antiretroviral use in Namibia. In this 
study 97% of the study subjects were started on treatments according to the Namibian 
antiretroviral therapy guidelines of 2003 (MoHSS, 2003), which was based on the WHO 
resource-limited settings guidelines of 2002 (WHO, 2006). Those started on treatments that 
were not specified by the 2003 ART guideline, were on treatments containing TDF instead of 
AZT or D4T. In this study 337 (67%) of the patients remained on their initial treatment for a 
median follow-up period of 37 months (IQR 28 – 43 months). This is comparable to other 
findings in resource poor settings (Schramm et al., 2008; Jahn et al., 2008). 
 
A total of 359 (72%) of the patients were started on ART with a CD4 cell count of ≤200 
cells/mm3. This was in line with the Nambian ART guidelines and WHO recommendations in 
similar resource poor settings (WHO, 2006). Several studies (Sterling et al., 2003; Lau, 
Gange and Moore, 2007; Stringer et al., 2006) have shown that people do poorly when 
starting at low CD4 cell count.  However, this study sample did not show a similar trend, as 
although more than two thirds of the sample started art at CD4 cell count of ≤200 cells/mm3, 
only about 24 (5%) patients were recorded to have virologic failure (virologic failure is 
defined as a follow-up CD4 cell count that is lower than the baseline CD4 cell count). This 
study could not determine any apparent reasons for the good prognosis of HAART patients at 
low CD4 cell count level, and it is contrary to what was found in other studies. 
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5.1. Substitution 
The rate of first ART substitution at 31% (157 patients) is similar to what was found in 
studies in other resource poor settings. A Botswana study found a rate of 32.2% (Wester et 
al., 2005), whereas a TREAT Asia Observational Database (TAHOD) study found a rate of 
39% (Srasuebkul et al., 2007). The rates in resource poor settings are much lower at 32% and 
39%, compared to what has been observed in developed countries (45%) (Mocroft et al., 
2001; Vo et al., 2008; Abgrall et al., 2006). In this study, females (60%), were more likely to 
substitute ARVs compared to their male counterparts. The higher rate for female ARV 
substitution could be due to pregnancies, since EFV is contra-indicated in pregnancy due to 
its possible teratogenocity (MoHSS, 2003). Some studies have also shown that female-gender 
is a risk factor for lactic acidosis and hepato-toxicity (Garcia-Benayas et al., 2003; John et al., 
2001; van Leth et al., 2005).  However, this study could not verify this finding due to high 
numbers of missing data and the reporting of toxicities that were unspecified. 
 
The median time before first substitution was 28 months. This was much longer than was 
reported in other studies in similar settings, a Malawian study (2008) reported 5 months and a 
South African study (2004) reported 42 days. In an Indian study, patients modified treatment, 
by substituting one or more antiretrovirals in their initial treatment within 40 days of 
treatment (Kumarasamy et al., 2006). Mocroft et al., (2001) reported that patients modified 
their treatment by six months. However, in this sample only 12 (2.4%) of the patients 
substituted antiretrovirals within the first six months. This much lower than what was found 
in the Indian study over the same period (Kumarasamy, 2006). 
 
The reason for this long duration and lower rates could be that clinicians want to preserve 
available treatments as long as possible for future use because the formulary is limited in 
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resource poor settings such as Namibia. It could also be that the patients in this sample have a 
better tolerance of the antiretrovirals in use. The reasons for the good tolerance to treatment 
of the patients in this sample were beyond the scope of this study and would require a 
separate study to explore this further. 
 
A total of nine (1.8%) of the patients underwent a second substitution. About equal male and 
female patients substituted ARVs for second time. The rate of second substitution is much 
lower than the 62% reported by Kirstein et al., 2002, in their United States study. As reported 
by Kistein et al., the median time (10 months) for moving from the second regimen to a third 
regimen is much shorter than moving from the first regimen to the second regimen (28 
months). ARV toxicities were the main reason for the second substitutions, with D4T and 
EFV being associated with the most adverse events. However, it must be noted that the 
sample size (N=9) was very small and this makes interpretation difficult.  
 
The most cited reason for first substitution was toxicities 98, both specified and unspecified 
toxicities. Unspecified toxicities constituted 18% (31), which is the highest reason for 
substituting antiretroviral medicines. This was similar to other studies in both the developing 
and developed world, where toxicities were the principle reasons for substituting ART 
medications (Mocroft et al., 2001; Kumarasamy et al., 2006; Wester et al., 2005). Being more 
than two years on D4T, 13 (8%), was the second reason for substituting ARVs. The ‘more 
than two years on D4T’ can also be cited as clinician’s choice as the patients’ treatments were 
modified because of the clinicians’ perceived possible toxicity due to D4T. This perception is 
justified because of the latest available literature on this medicine (D4T), and even the new 
Namibian ART guideline (2007) indicates the substitution of D4T when required (MoHSS, 
2007).  Pulmonary Tuberculosis (PTB) was the third most commonly reported reason for 
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ARV substitutions at 7% (12). The modification due to PTB is due to the interaction of 
nevirapine with PTB regimen, especially rifampicin (MoHSS, 2003). Nevertheless, the 
findings are similar with findings in other studies that toxicities are the main reasons for 
modifying ART.  
 
5.2. Toxicities 
The most reported specified toxicities were peripheral neuropathy 7% (12), lipo-dystrophy 
3% (5) and lipo-atrophy 1% (2). These toxicities were similar to those indicated in other 
studies in resource poor settings, although the rates were not similar. In the TAHOD study 
lipo-atrophy was leading toxicity of ART change, whereas it was peripheral neuropathy in 
this study.  A Ugandan study by Forna et al., (2007) found peripheral neuropathy as the 
leading reason for modifying ART, which was similar to the finding of this study.  
 
D4T was the ARV with most reported toxicities (130), followed by NVP (27). This 
corresponded to finding in other studies (Brinkman et al., 1998; Murphy et al., 2002) that 
NRTI are mitochondrial DNA toxic, resulting in several adverse effects. The fact that D4T, a 
NRTI, was found to be associated with more adverse events such as peripheral neuropathy, 
lipo-dystrophy and lipoatrophy confirm the mitochondrial toxicity of this ARV in the patients 
of this study. NVP was associated with the second highest toxicities after D4T, namely 
peripheral neuropathy, impotence, bone marrow depression, jaundice and NVP 
hypersensitivity. The high number of PTB that is record with NVP is due to interaction of 
NVP with PTB medicines such as rifampicin (MoHSS, 2008), as stated earlier. In order avoid 
this drug interaction, ART patients that are started on NVP containing antiretroviral therapy 
replace the nevirapine with efavirenz (MoHSS, 2008). 
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However, one of the major limitations of this study was the high number of unspecified 
toxicities. Out of a total of 57 reported toxicities, 30 (53%) were not specified and simply 
indicated as ‘toxicity’. This is probably due to the design of the form that the clinicians were 
using when they were having consultations with patients. This form did not make provision 
for writing a specific toxicity or did not list the specific toxicities but only provided a tick box 
for ‘toxicity’. It is worth noting that in 75 (43%) of the substitutions the reasons were not 
indicated. This could be an indication that there is need for training clinicians in recording 
and reporting suspected adverse drug reactions. 
 
5.3. Switching 
The rate of switching from a first line to second line ART was only 1.2% (six patients), 
which is much lower than what was found in other studies. A South African study found that 
8.7% of the patients changed to a second line (Coetzee et al., 2004) and the TAHOD study 
found that 6% changed to second line (Srasuebkul et al., 2007). The reason for these low 
rates could again be that the clinicians have limited choices and thus are trying to preserve 
treatment options for future use, as pointed out in the TAHOD study. The median time to 
switch treatment was found to be 31 months with an inter-quartile range (24 – 39 months), 
which is similar to findings in other studies (Clearly, McIntyre and Boulle, 2006; Coetzee et 
al., 2004) in resource poor settings that indicate that changes take longer to occur in these 
settings. In developed countries up to 62% of the patients switched to second line within 12 
months of starting their antiretroviral therapy (Kistein et al., 2002; Vo et al., 2008). This 
could be because of the availability of a larger number of treatment options available to 
clinicians, should the patients experience problems with their current regimens. In addition, 
the clinicians in these settings have better access to laboratory tests for closer monitoring of 
their patients’ condition.  
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In three of the six patients, the reason recorded for switching to second line ART was a high 
viral load, which is an indication of treatment failure. This finding was similar to that 
reported by other studies in that patients’ switched to second line ART due to treatment 
failure (Kumarasamy et al., 2006; Pujades-Rodrigues et al., 2008). Of these three patients 
who had high viral load, two patients (67%) started ART with CD4 cell count that was <200 
cells/mm3  and one (33%) had a CD4 count that was less than the baseline CD4 count at the 
time of switch. It is reported that if a follow-up CD4 cell count is lower than the initial CD4 
cell count that it was a possible predictor of treatment failure. This finding indicated that CD4 
count was not a sensitive enough predictor of treatment failure. CD4 cell count might be 
relatively high (higher than the initial CD4 cell count), but the viral load might be increasing 
due to ineffective treatment. However, because of the unavailability of viral load test, which 
is a more reliable determinant of treatment failure, clinicians in resource poor settings are 
compelled to rely on the reduction of CD4 cell counts to make their clinical decisions, 
especially in asymptomatic patients.  
 
One patient was switched due to toxicity. This is interesting as toxicities are mainly taken 
care of by substituting the offending drug. It is not clear from the available data whether the 
patient had exhausted all the available options and thus the clinician was left with no option 
than to switch to a second line therapy. The sample size was also very small and the results 
should be interpreted cautiously.  
 
Another interesting observation in this study sample was that those who started on second 
line ART, five (16%) were moved back to first line ART, that is, ART without a PI. The main 
reason for this reversal was indicated as toxicity, with LPV/r being the ARV associated with 
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the toxicity. However, some clinicians that made this modification questioned the 
appropriateness of starting these patients on a second line therapy in the first place. The 
patient records also did not indicate the reason for this initial decision. In the absence of 
proper notes to inform the clinicians of the initial decision, they had no other option but to put 
the patients back on first line treatment. The rationale of putting these patients on first line 
treatment would probably be to preserve the PI treatment for the patients’ future use. 
However, it could be limiting to the clinicians if the first line treatment failed, the clinicians 
would not have alternatives as the PI-based second line treatments would be ‘toxic’ to the 
patients. This requires an expansion of the currently available formulary to include treatments 
that do use the same or similar mechanism to the ones currently available.  
 
5.4. Clinical records and reporting  
An issue that was highlighted by this study was poor record keeping in patients clinical notes. 
This was evidenced by clinicians not specifying details of reasons for substituting or 
switching antiretroviral therapy. In addition, on many occasions clinicians did not give the 
specific toxicities for substituting antiretrovirals. This made interpretation of their decisions 
to substitute or switch ARVs difficult. It is critical that full details of all patients’ treatments 
are documented in clinical notes, and this is particularly important for monitoring new 
treatments such as HAART which are complex and utilise new, potent and potentially toxic 
drugs. These findings point to the need to ensure that clinicians’ record detailed patient notes 
and to educate them to report all adverse drug reactions to the newly established Therapeutic 
Information and Pharmacovigilance Centre, in Windhoek.  This will ensure that critical 
information on the antiretroviral therapy programme will be more readily available to 
programme managers and the Ministry of Health and Social Services. 
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CHAPTER 6: CONCLUSIONS AND RECOMMENDATIONS  
6.1. Conclusions 
In this study it was found that the Namibian clinicians closely followed the ART guideline, as 
93% of the patients were started on treatments according to the guideline. Two thirds (337) of 
the patients remained on their initial treatment for median period of 37 months.  
 
The rate of substitution of 31% is similar to that found in other resource poor settings and the 
most reported reason for modifying ART was toxicity. The most reported toxicities for 
substituting ARV were peripheral neuropathy (7%), followed by lipodystrophy (3%). These 
toxicities are similar to those reported in similar settings. D4T and NVP were the 
antiretrovirals mostly associated with toxicities, and again this is similar to findings in other 
resource poor settings, as well as in developed countries. 
 
The rate of switching, at 1.2%, was much lower than is found in other resource poor settings. 
This could be due to several reasons, including that clinicians were trying to preserve 
treatment as long as possible because of the limited formulary available to them. 
Alternatively, Namibian patients may tolerate the first line treatments well, although it was 
beyond the scope of this study to investigate this aspect. High viral load was identified as the 
principle reason for switching ART.  
 
 It must be noted that in 75 (43%) and 2 (33%) of the cases the reasons for substituting and 
switching, respectively, were not stated. Additionally, in 31 (18%) of the cases of first 
substitution and 2 (22%) of the cases of second substitution the reason was given broadly as 
“toxicity”. This made it difficult to reliably quantify the reasons for modification of ART.  It 
indicated that steps must be taken to ensure clinicians accurately document in patient records 
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the reasons why a particular treatment was changed. It also pointed to poor reporting on 
adverse effects of these medicines, which is essential in assessing the effectiveness of these 
new medicines and the ART programme. 
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6.2. Recommendations 
 
1. D4T and NVP are the ARVs mainly associated with toxicities and patients on these 
drugs should be closely monitored. 
 
2. The Ministry of Health and Social Services should regularly update the antiretroviral 
therapy guidelines as new and less toxic antiretrovirals become available to patients. 
 
3. The Ministry of Health and Social Services should carry out a national study to 
determine the rate of substitution and switching in the antiretroviral therapy 
programme. 
 
4. Further investigations should be carried out on the suitability of the patient record 
forms currently in use and the training provided for clinicians in adverse event 
recording and reporting. 
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APPENDICES 
 
APPENDIX A 
 
DATA COLLECTION TOOL 
Patient Reference Number: ______/________        ART Site: _____________________                                 
Pharmacy ref number: ___________      Date of data collection: _______/_______/______    
                                                                                                                                                                          dd               mm               yyyy 
A. Demographic Information 
1. Date of Birth:  
    a. __ /__ /____  
              dd          mm           yyyy 
    b. Age at ART initiation: ________    
 
2. Sex:    
    a. Male           
    b. Female         
     
3. Home Language: 
 
4. Treatment Supporter: 
   a. Yes    
  b. No    
    c. If yes, specify relationship: 
 
B. Treatment Information 
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5. Date of ART Initiation:  ___ /___ /_____            
                                                dd            mm               yyyy 
6. Initial ART regimen (specify drugs):______________________  
7. Date of 1st Substitution: ____/___/___                              Time to 1st Subst:______ 
                                              dd           mm     yyyy                                                                                         months 
    1st Substitution (specify drug(s)) _____________________ 
 
     Reason for Substitution:_____________________________________                                      
 
2nd Substitution (specify drug(s)) _____________________  ___/____/____ Time to 2nd Subst:_____ 
                                                                                                    dd         mm    yyyy                                                      months 
     Reason for Substitution:_____________________________________                                      
 
3rd Substitution (specify drug(s)) _____________________  ___/____/____  Time to 3rd Subst:_____ 
                                                                                                    dd      mm       yyyy                                                       months 
     Reason for Substitution:_____________________________________                                      
 
8. Date of 1st Switch: ____/_____/_____                     Time to 1st Switch _____ 
                                     dd         mm        yyyy                                                                                        months 
     1st Switch (specify drug(s))____________________________     
      Reason for Switch:_____________________________________ 
 
2nd Switch_(specify drug(s))________________________ ____/____/___     Time to 2nd Switch_____ 
                                                                                                          dd      mm     yyyy                                               months 
      Reason for Switch_______________________________ 
 
3rd Switch_(specify drug(s))__________________________   ___/____/___  Time to 3rd Switch_____
                                                                                                          dd        mm    yyyy                                               months 
      Reason for Switch_______________________________ 
 
 
C. Clinical Outcome 
9. Weight: 
 
a. At Start of ART______________(kg) 
 
b. Most recent_________________(kg) 
D. Immunological Outcome – CD4 Count 
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11. CD4 count at start of ART: 
      a. _______________ 
       
 
12. Follow-up CD4: 
 
       a. 1st Substitution/switch ________ (Date: :  ___ / ___/____)     
                                                                           dd      mm      yyyy 
       b. 2nd Substitution/switch: _________  (Date: :  ___ / ___/____)     
                                                                                 dd      mm      yyyy 
       c. 3rd Substitution/switch: _________  (Date: :  ___ / ___/____)     
                                                                               dd       mm      yyyy 
       d. Most recent CD4 on ART: _________  (Date: :  ___ / ___/____)     
                                                                           dd       mm      yyyy 
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APPENDIX B 
 
Johannes Gaeseb 
P. O. Box 8861 
Bachbrecht 
Windhoek 
6 December 2007 
The Permanent Secretary 
Ministry of Health and Social Services 
Private Bag 13366 
Windhoek 
Namibia 
 
Dear Sir, 
 
Re: Request for permission to do research at the Katutura Intermediate Hospital 
 
I am a final year Master in Public Health student at the University of the Western Cape. In 
order to complete my degree I am required to do a mini-thesis on a research topic of my 
choice, but that has relevance to my current work. 
 
It is in line with this requirement that I am requesting your good office to allow me to do my 
research at the Katutura Intermediate Hospital. My research title is “To Describe the extent 
and reasons for substituting and switching Highly Active Antiretroviral Therapy at the 
Katutura Intermediate Hospital in Windhoek, Namibia”. This is a retrospective study and I 
will be required to access medical records of patients on HAART. However, it does not 
require any interaction with patients and very minimal interaction with clinical staff.  
 
The confidentiality of patient information will ensured by means of patient codes. No patient 
names will appear on the data collection tool. The collected data will also be kept 
confidential. It will be kept in a locked steel cupboard in a locked office, if not in use. The 
computer that will be use for data entry and analysis is pass word protected. No names or any 
means of identification will be used in the report. The results of the study will be made 
available to KIH ART Clinic clinical staff, management of KIH and the management of 
MoHSS.  
 
Please find attached my research protocol for your consideration. 
 
Yours sincerely, 
 
 
Johannes Gaeseb 
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APPENDIX C 
Johannes Gaeseb 
P. O. Box 8861 
Bachbrecht 
Windhoek 
 
The Senior Medical Supertiendent 
Katutura Intermediate Hospital 
Private Bag 13366 
Windhoek 
Namibia 
 
Dear Sir, 
 
Re: Request for permission to access the patient files at the Katutura ART Clinic 
 
I am a final year Master of Public Health student at the University of the Western Cape. In 
order to complete my degree I am required to do a mini-thesis on a research topic of my 
choice, but that has relevance to my current work. 
 
My research study is entitled “To Describe the extent and reasons for substituting and 
switching Highly Active Antiretroviral Therapy at the Katutura Intermediate Hospital in 
Windhoek, Namibia”. This is a retrospective study and does not require any interaction with 
patients and very minimal interaction with clinical staff.  
 
I intend to make use of the patient files at the your hospital to collect the data for my study. 
Therefore, I am herewith requesting your good office to give me permission to access the 
patient file at the ART clinic.Say how you will protect confidentiality etc 
 
I have already received approval for this study from the following institutions: 
1) Ministry of Health and Social Services 
2) University of the Western Cape Ethics Committee 
3) University of the Western Cape Higher Degrees Committee. 
 
Please find attached copies of the above-mentioned approvals and my research protocol for 
your easy reference. 
 
Yours sincerely, 
 
Johannes Gaeseb 
 
 
 
 
 
 
